PF-3644022 is a potent freely reversible ATP-competitive inhibitor of MAPKAPK2 (MK2) with an Ki of 3 nM. This compound also potently inhibits TNFα production with an IC50 of 160 nM.
research use only
Cat.No.S8224
|
In vitro |
DMSO
: 75 mg/mL
(200.28 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 374.46 | Formula | C21H18N4OS |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1276121-88-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1CNC2=C(SC3=C2C4=C(C=C3)N=C(C=C4)C5=CN=C(C)C=C5)C(=O)N1 | ||
| Targets/IC50/Ki |
MK2
3 nM(Ki)
TNFα
160 nM
|
|---|---|
| In vitro |
PF-3644022 is a potent freely reversible ATP-competitive compound that inhibits Mitogen-activated protein kinase-activated protein kinase 2(MK2) activity with good selectivity when profiled against 200 human kinases. In the human U937 monocytic cell line or peripheral blood mononuclear cells, this compound potently inhibits TNFα production with similar activity. It blocks TNFα and IL-6 production in LPS-stimulated human whole blood.<sup><a class="sref" href="#s_ref">[1]</a></sup> |
| Kinase Assay |
In Vitro Kinase Assays and Inhibition Kinetics.
|
|
The kinase activity of MK2 is assayed by using fluorescently labeled heat shock protein 27 (HSP27) peptide and a Caliper LabChip 3000. Phosphorylated peptide is separated from substrate peptide electrophoretically and quantified. All kinase reactions are performed at room temperature in 20 mM HEPES, containing 10 mM MgCl2, 1 mM dithiothreitol, 0.01% bovine serum albumin, and 0.0005% Tween 20, pH 7.5. For endpoint experiments, reactions are terminated during the linear phase by the addition of 30 mM EDTA. The kinase selectivity experiments are performed with the MgATP concentration fixed at the Km(app) determined for each enzyme. The initial velocitie is determined in the presence and absence of this compound with ATP as the varied substrate while the HSP27 peptide concentration is held constant.
|
|
| In vivo |
PF-3644022 displays good pharmacokinetic parameters in rats and is orally efficacious in both the rat acute LPS-induced TNFα model and the chronic streptococcal cell wall-induced arthritis model,with ED50 values of 6.9 and 20 mg/kg, respectively.<sup><a class="sref" href="#s_ref">[1]</a></sup> |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.